Daratumumab granted breakthrough drug status

Expert Opinion on Investigational Drugs

Volumn 23, Issue 4, 2014, Pages 445-452

  Laubach, Jacob P ^a   Tai, Yu Tzu ^a   Richardson, Paul G ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; Complement dependent cytotoxicity; Daratumumab; Multiple myeloma

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CD38 ANTIGEN; DARATUMUMAB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISOLONE; THALIDOMIDE;

ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL SURFACE; CELL VIABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; HUMANS; MULTIPLE MYELOMA;

EID: 84896142443     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.889681     Document Type: Review

References (56)

1. Malavasi F, Funaro A, Roggero S, et al. Human CD38: a glycoprotein in search of a function. Immunol Today 1994;15(3):95-7 (Pubitemid 24076322)
2. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001;25(1):1-12 (Pubitemid 32012975)
3. Hara-Yokoyama M, Kukimoto-Niino M, Terasawa K, et al. Tetrameric interaction of the ectoenzyme CD38 on the cell surface enables its catalytic and raft-association activities. Structure 2012;20(9):1585-95
4. Zhao YJ, Lam CM, Lee HC. The membrane-bound enzyme CD38 exists in two opposing orientations. Sci Signal 2012;5(241):ra67 .
5. Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008;88(3):841-86
6. Malavasi F, Deaglio S, Damle R, et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011;118(13):3470-8
7. Buggins AG, Pepper C, Patten PE, et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res 2010;70(19):7523-33
8. Vaisitti T, Aydin S, Rossi D, et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010;24(5):958-69
9. Funaro A, Spagnoli GC, Ausiello CM, et al. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J Immunol 1990;145(8):2390-6 (Pubitemid 20374554)
10. Ausiello CM, Urbani F, la Sala A, et al. CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes. Eur J Immunol 1995;25(5):1477-80
11. Deaglio S, Dianzani U, Horenstein AL, et al. Human CD38 ligand. A 120- KDA protein predominantly expressed on endothelial cells. J Immunol 1996;156(2):727-34 (Pubitemid 26028931)
12. Horenstein AL, Stockinger H, Imhof BA, Malavasi F. CD38 binding to human myeloid cells is mediated by mouse and human CD31. Biochem J 1998;330(Pt 3):1129-35 (Pubitemid 28161986)
13. Howard M, Grimaldi JC, Bazan JF, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 1993;262(5136):1056-9 (Pubitemid 24035045)
14. Aarhus R, Graeff RM, Dickey DM, et al. ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem 1995;270(51):30327-33
15. Lee HC. Structure and enzymatic functions of human CD38. Mol Med 2006;12(11-12):317-23 (Pubitemid 46489826)
16. Hubert S, Rissiek B, Klages K, et al. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp Med 2010;207(12):2561-8
17. Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer 2012;12(11):741-52
18. Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005;105(8):3042-50
19. Deaglio S, Vaisitti T, Aydin S, et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108(4):1135-44 (Pubitemid 44232007)
20. Ferretti E, Bertolotto M, Deaglio S, et al. A novel role of the CX3CR1/ CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia 2011;25(8):1268-77
21. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121(4):482-8 (Pubitemid 38392955)
22. Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 2012;26(12):2530-7
23. Hosen N. Multiple myeloma-initiating cells. Int J Hematol 2013;97(3):306-12
24. Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 2005;19(12):2264-72 (Pubitemid 41741623)
25. Granziero L, Circosta P, Scielzo C, et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood 2003;101(5):1962-9 (Pubitemid 36237600)
26. Mihara K, Bhattacharyya J, Kitanaka A, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia 2012;26(2):365-7 .
27. Mihara K, Yanagihara K, Takigahira M, et al. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J Immunother 2009;32(7):737-43
28. Stevenson FK, Bell AJ, Cusack R, et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 1991;77(5):1071-9
29. Goldmacher VS, Bourret LA, Levine BA, et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994;84(9):3017-25 (Pubitemid 24328093)
30. Ellis JH, Barber KA, Tutt A, et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 1995;155(2):925-37
31. Flavell DJ, Boehm DA, Emery L, et al. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int J Cancer J Int Cancer 1995;62(3):337-44
32. Bolognesi A, Polito L, Farini V, et al. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia. J Biol Regul Homeost Agents 2005;19(3-4):145-52 (Pubitemid 351515918)
33. Lokhorst H, Plesner T, Gimsing P, et al. Daratumumab, A CD38 monoclonal antibody study in advanced multiple myeloma - an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study. Haematologica 2013;98(s1):241
34. Lokhorst HM, Plesner T, Gimsing P, et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin 2013;31(Suppl):8512
35. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186(3):1840-8
36. Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, et al. Daratumumab, a novel human anti-CD38 monoclonal antibody for the treatment of chronic lymphocytic leukemia and B-cell non-hodgkin lymphoma. ASH Annu Meeting Abstr 2012;120(21):3935
37. Groen RW, Noort WA, Raymakers RA, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012;120(3):e9-e16
38. Noort WA, Groen RW, Raymakers R, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of refractory patient-derived multiple myeloma cells, growing in a novel humanized mouse MM model. ASH Annu Meeting Abstr 2012;120(21):940
39. Noort WA, Groen RW, Raymakers R, et al. Daratumumab, a novel human CD38 monoclonal antibody for treatment of multiple myeloma, prevents intramedullary spreading of patient derived multiple myeloma cells growing in a humanized mouse model. ASH Annu Meeting Abstr 2012;120(21):1834
40. Jansen JH, Boross P, Overdijk MB, et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. ASH Annu Meeting Abstr 2012;120(21):2974
41. Kong SY, Li XF, Nahar S, et al. Daratumumab directly induces human multiple myeloma cell death and acts synergistically with conventional and novel anti-myeloma drugs. ASH Annu Meeting Abstr 2010;116(21):3013
42. van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 2011;1(10):e41
43. Overdijk MB, Verploegen S, Marijn B, et al. Phagocytosis is a mechanism of action for daratumumab. ASH Annu Meeting Abstr 2012;120(21):4054
44. Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009;114(17):3625-8
45. van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011;96(2):284-90
46. Plesner T, Lokhorst H, Gimsing P, et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I/II study. ASH Annu Meeting Abstr 2012;120(21):73
47. Plesner T, Lokhorst HM, Gimsing P, et al. Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: preliminary efficacy data from a multicenter phase I/ II study. ASCO Meeting Abstr 2012;30(15-Suppl):8019
48. Lokhorst HM, Plesner T,Gimsing P, et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. ASCO Meeting Abstr 2013;31(15-Suppl):8512
49. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117(18):4691-5
50. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120(3):552-9
51. Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012;30(16):1953-9
52. Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti- CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012;30(16):1960-5
53. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341(21):1565-71
54. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114(4):772-8
55. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352(24):2487-98 (Pubitemid 41007864)
56. Plesner T, Arkenau T, Lokhorst H, et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstr 2013;122:1986